Drug Profile
OMTX 505
Alternative Names: MTX5-NIG; OMTX-505Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Oncomatryx
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Ribosome inactivating protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Breast cancer in Spain (unspecified route) (Oncomatryx pipeline, September 2023)
- 12 Sep 2023 Discontinued - Preclinical for Lung cancer in Spain (unspecified route) (Oncomatryx pipeline, September 2023)
- 12 Sep 2023 Discontinued - Preclinical for Pancreatic cancer in Spain (unspecified route) (Oncomatryx pipeline, September 2023)